Novo Nordisk stock is trading near $50, a level that captures both a sharp rebound and a steep loss of confidence. The shares have recovered from a 52-week low of $35.12, yet they still sit about 75% below the June 2024 peak of $142.44.
That collapse has erased roughly $470 billion in market value from a former European heavyweight once worth about $640 billion. The recent bounce has been driven by strong early demand for the oral Wegovy pill and a first-quarter earnings beat, but investors are still weighing whether the stock is a turnaround story or a value trap.
At around 11.8 times forward earnings and with a dividend yield near 3.6%, Novo Nordisk stock is attracting bargain hunters. The challenge is that cheaper valuation alone may not offset intensifying competition from Eli Lilly, pricing pressure in the US market, and repeated setbacks for next-generation obesity treatments.
Key Facts
- Novo Nordisk’s US-listed shares are trading near $50, down about 43% from a year ago and roughly 75% below the June 2024 peak of $142.44.
- The company has fallen from an approximate market value of $640 billion to about $168 billion, a decline of roughly $470 billion.
- First-quarter sales rose 32% at constant exchange rates to DKK 96.8 billion, or about $15.2 billion, helped by obesity drug demand.
- The oral Wegovy pill generated about 50,000 weekly prescriptions by late January and has surpassed 2 million US prescriptions since launch.
- CagriSema failed to meet a key non-inferiority endpoint against Lilly’s rival therapy in REDEFINE 4, with weight-loss differences of 2.5 to 3.4 percentage points favoring the competitor.
Novo Nordisk Stock
The central issue for Novo Nordisk is whether its recent stabilization can develop into a durable recovery. The company still controls major franchises in diabetes and obesity through Ozempic and Wegovy, but the market no longer assigns it the premium status it enjoyed when GLP-1 drugs appeared to offer nearly unchallenged growth. The stock’s collapse reflects a reset in expectations rather than a simple earnings wobble.
The biggest reason is competition from Eli Lilly, whose obesity and diabetes portfolio has gained momentum through stronger growth and better comparative efficacy in key studies. In a market where prescribers increasingly focus on measurable weight-loss outcomes, head-to-head trial results matter. That has made Novo’s pipeline disappointments especially costly, because the company needed a next-generation answer to defend share and pricing power.
What has changed in recent months is the emergence of the oral Wegovy pill as a credible growth driver. An oral option broadens the addressable market beyond patients willing to use injectables, and early prescription data suggest meaningful demand. That matters not only for revenue, but also for investor confidence that Novo can still innovate within a category it helped define.
Novo Nordisk at $50 is no longer priced as a market darling; it is priced as a company that must prove its obesity franchise can still grow despite Lilly’s lead.
Why the oral Wegovy launch matters
The oral Wegovy rollout is the clearest positive catalyst in the story. Early uptake has been strong, with management pointing to blockbuster launch dynamics and a leading share of new US prescriptions for the Wegovy brand. The product offers convenience, expands physician reach, and may help defend the semaglutide franchise against rivals launching their own oral therapies.
Just as important, the pill appears to be adding demand rather than simply shifting patients away from Novo’s injectable products. If that pattern holds through the second half of 2026 and into international markets, it could soften the effect of slower growth elsewhere in the portfolio.
Implications for Investors
For investors, Novo Nordisk now sits in a classic low-multiple debate. On one side, the shares look inexpensive after the drawdown, especially with forward earnings of about 11.8 times and a dividend yield around 3.6%. On the other, the discount reflects real structural risks: Lilly’s stronger competitive position, pressure on US drug pricing, and the gradual erosion of intellectual property around semaglutide.
The next major watch-point is earnings execution. First-quarter sales rose 32% at constant exchange rates to DKK 96.8 billion, and guidance was improved to reflect an adjusted sales and operating profit decline of 4% to 12%, versus prior expectations of a 5% to 13% decline. That was a step in the right direction, but investors will want to see whether oral Wegovy momentum can continue driving upside in the second quarter and through a broader international rollout.
Portfolio positioning depends on risk tolerance. Value-oriented investors may see a high-quality pharmaceutical company trading far below historical multiples, with substantial cash generation and a still-important role in obesity care. More cautious investors may prefer to wait for evidence that Novo can stabilize market share and produce stronger pipeline wins before assigning a higher multiple. Either way, volatility is likely to remain elevated given the wide range of possible outcomes.
The path forward for Novo Nordisk hinges on whether oral Wegovy can offset competitive losses and rebuild growth credibility. Upcoming earnings, prescription trends, and further pipeline data will determine whether the stock’s recovery extends beyond a rebound from deeply oversold levels.